Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Preferred Stock Liabilities: 2017-2021

Historic Preferred Stock Liabilities for Cogent Biosciences (COGT) over the last 1 years, with Sep 2021 value amounting to $85.4 million.

  • Cogent Biosciences' Preferred Stock Liabilities fell 38.22% to $85.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $85.4 million, marking a year-over-year decrease of 38.22%. This contributed to the annual value of $110.9 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Cogent Biosciences reported Preferred Stock Liabilities of $85.4 million as of Q3 2021, which was down 0.00% from $85.4 million recorded in Q2 2021.
  • Cogent Biosciences' 5-year Preferred Stock Liabilities high stood at $138.2 million for Q3 2020, and its period low was $77.2 million during Q4 2017.
  • For the 2-year period, Cogent Biosciences' Preferred Stock Liabilities averaged around $102.9 million, with its median value being $94.7 million (2021).
  • Data for Cogent Biosciences' Preferred Stock Liabilities shows a maximum YoY slumped of 38.22% (in 2021) over the last 5 years.
  • Over the past 4 years, Cogent Biosciences' Preferred Stock Liabilities (Quarterly) stood at $77.2 million in 2017, then reached $77.2 million in 2018, then reached $110.9 million in 2020, then plummeted by 38.22% to $85.4 million in 2021.
  • Its Preferred Stock Liabilities stands at $85.4 million for Q3 2021, versus $85.4 million for Q2 2021 and $94.7 million for Q1 2021.